Eupraxia Pharmaceuticals Inc. (EPRX) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
EPRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
EPRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export EPRX earnings history in CSV or JSON format
Free sign-in required to download data
Eupraxia Pharmaceuticals Inc. (EPRX) Earnings Overview
As of May 8, 2026, Eupraxia Pharmaceuticals Inc. (EPRX) reported trailing twelve-month net income of -$47M, reflecting -38.2% year-over-year growth. The company earned $-0.91 per diluted share over the past four quarters.
Looking at the long-term picture, EPRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 2020.
Eupraxia Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PACB (-$546M net income, -341.5% margin), IRWD ($151M net income, 8.1% margin), PTGX (-$115M net income, -282.8% margin), EPRX has comparable earnings metrics. Compare EPRX vs PACB →
EPRX Earnings vs Peers
Earnings metrics vs comparable public companies
EPRX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$39M | -6.9% | -$39M | $-1.05 | - | - |
| 2024 | -$37M | -30.0% | -$39M | $-0.76 | - | - |
| 2023 | -$28M | -52.6% | -$28M | $-1.17 | - | - |
| 2022 | -$18M | -2.5% | -$18M | $-0.96 | - | - |
| 2021 | -$18M | -350.1% | -$15M | $-1.61 | - | - |
| 2020 | -$4M | +45.7% | -$2M | $-0.31 | - | - |
| 2019 | -$7M | +44.1% | -$7M | $-0.56 | - | - |
| 2018 | -$13M | -201.1% | -$12M | $-1.03 | - | - |
| 2017 | -$4M | - | -$5M | $-0.34 | - | - |
See EPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEPRX — Frequently Asked Questions
Quick answers to the most common questions about buying EPRX stock.
Is EPRX growing earnings?
EPRX EPS fell to $-0.91, with earnings declining -38.2%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-47M.
What are EPRX's profit margins?
Eupraxia Pharmaceuticals Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are EPRX's earnings?
EPRX earnings data spans 2017-2025. The declining earnings trend is -38.2% YoY. Historical data enables comparison across business cycles.